Heart failure (HF) and chronic kidney disease (CKD) are two pathological conditions with a high prevalence in the general population. When they coexist in the same patient, a strict interplay between them is observed, such that patients affected require a clinical multidisciplinary and personalized management. The diagnosis of HF and CKD relies on signs and symptoms of the patient but several additional tools, such as blood-based biomarkers and imaging techniques, are needed to clarify and discriminate the main characteristics of these diseases. Improved survival due to new recommended drugs in HF has increasingly challenged physicians to manage patients with multiple diseases, especially in case of CKD. However, the safe administration of these drugs in patients with HF and CKD is often challenging. Knowing up to which values ​​of creatinine or renal clearance each drug can be administered is fundamental. With this review we sought to give an insight on this sizable and complex topic, in order to get clearer ideas and a more precise reference about the diagnostic assessment and therapeutic management of HF and CKD.

Assessment and management of heart failure in patients with chronic kidney disease / A.I. Guaricci, F. Sturdà, R. Russo, P. Basile, A. Baggiano, S. Mushtaq, L. Fusini, F. Fazzari, F. Bertandino, F. Monitillo, M.C. Carella, M. Simonini, G. Pontone, M.M. Ciccone, G. Grandaliano, G. Vezzoli, F. Pesce. - In: HEART FAILURE REVIEWS. - ISSN 1573-7322. - (2023), pp. 1-16. [Epub ahead of print] [10.1007/s10741-023-10346-x]

Assessment and management of heart failure in patients with chronic kidney disease

A. Baggiano;G. Pontone;
2023

Abstract

Heart failure (HF) and chronic kidney disease (CKD) are two pathological conditions with a high prevalence in the general population. When they coexist in the same patient, a strict interplay between them is observed, such that patients affected require a clinical multidisciplinary and personalized management. The diagnosis of HF and CKD relies on signs and symptoms of the patient but several additional tools, such as blood-based biomarkers and imaging techniques, are needed to clarify and discriminate the main characteristics of these diseases. Improved survival due to new recommended drugs in HF has increasingly challenged physicians to manage patients with multiple diseases, especially in case of CKD. However, the safe administration of these drugs in patients with HF and CKD is often challenging. Knowing up to which values ​​of creatinine or renal clearance each drug can be administered is fundamental. With this review we sought to give an insight on this sizable and complex topic, in order to get clearer ideas and a more precise reference about the diagnostic assessment and therapeutic management of HF and CKD.
Biomarkers; Cardio-renal syndrome; Chronic kidney disease; Guidelines-directed medical therapy; Heart failure
Settore MED/11 - Malattie dell'Apparato Cardiovascolare
2023
20-set-2023
Article (author)
File in questo prodotto:
File Dimensione Formato  
2023 Heart Fail Rev (Assessment and management of HF in CKD).pdf

accesso aperto

Descrizione: Review
Tipologia: Publisher's version/PDF
Dimensione 1.13 MB
Formato Adobe PDF
1.13 MB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/1006653
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 1
  • ???jsp.display-item.citation.isi??? ND
social impact